Recent molecules in the treatment of severe infections caused by ESBL-producing bacteria

References

• Bassetti M, Poulakou G, Ruppe E, et al. Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive Care Med. 2017;43:1464–1475.
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Hsueh P-R, Mendes RE, et al. The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother. 2019;63:63.
   Web of Science ®Google Scholar
• Harris PNA, Tambyah PA, Lye DC, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA. 2018;320:984.
   PubMed Web of Science ®Google Scholar
• Montravers P, Bassetti M. The ideal patient profile for new beta-lactam/beta-lactamase inhibitors. Curr Opin Infect Dis. 2018;31:587–593.
   PubMed Web of Science ®Google Scholar
• Schwaber MJ, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA. 2008;300:29113.
   Web of Science ®Google Scholar
• Wilcox MH. The tide of antimicrobial resistance and selection. Int J Antimicrob Agents. 2009;34:S6–10.
   PubMed Web of Science ®Google Scholar
• Liew YX, Lee W, Kwa AL, et al. Inappropriate carbapenem use in Singapore public hospitals: opportunities for antimicrobial stewardship. Int J Antimicrob Agents. 2011;37:87–88.
   PubMed Web of Science ®Google Scholar
• Xue Fen Seah V, Yue Ling Ong R, Shi Yuan Lim A, et al. Impact of a carbapenem antimicrobial stewardship program on patient outcomes. Antimicrob Agents Chemother. 2017;61:e00736–17.
   PubMed Web of Science ®Google Scholar
• Patrier J, Timsit J-F. Carbapenem use in critically ill patients. Curr Opin Infect Dis. 2020;33:86–91.
   PubMed Web of Science ®Google Scholar
• Lee N-Y, Lee -C-C, Huang W-H, et al. Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility. Antimicrob Agents Chemother. 2012;56:2888–2893.
   PubMed Web of Science ®Google Scholar
• Wu U-I, Chen W-C, Yang C-S, et al. Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis. Inter J Infect Dis. 2012;16:e47–52.
   PubMed Web of Science ®Google Scholar
• Karaaslan A, Kadayifci EK, Atici S, et al. The clinical efficacy and safety of ertapenem for the treatment of complicated urinary tract infections caused by ESBL-producing bacteria in children. Int J Nephrol. 2015;2015:1–4.
   Web of Science ®Google Scholar
• Vardakas KZ, Tansarli GS, Rafailidis PI, et al. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum -lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67:2793–2803.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Han JH, Rock C, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum -lactamase bacteremia. Clin Infect Dis. 2015. cited 2020 Feb 12. Available at https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/civ003
   Web of Science ®Google Scholar
• Palacios-Baena ZR, Gutiérrez-Gutiérrez B, Calbo E, et al. Empiric therapy with carbapenem-sparing regimens for bloodstream infections due to extended-spectrum β-lactamase–producing enterobacteriaceae: results from the INCREMENT cohort. Clin Infect Dis. 2017;65:1615–1623.
   PubMed Web of Science ®Google Scholar
• Russo A, Falcone M, Gutiérrez-Gutiérrez B, et al. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae. Int J Antimicrob Agents. 2018;52:577–585.
   PubMed Web of Science ®Google Scholar
• Retamar P, López-Cerero L, Muniain MA, et al. the ESBL-REIPI/GEIH group. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing escherichia coli. Antimicrob Agents Chemother. 2013;57:3402–3404.
   PubMed Web of Science ®Google Scholar
• Sharara SL, Amoah J, Pana ZD, et al. Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by ESBL-producing organisms? Clin Infect Dis. 2019;69:ciz1205. [online ahead of print].
   Google Scholar
• Gutiérrez-Gutiérrez B, Rodríguez-Baño J. Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients. Clin Microbiol Infect. 2019;25:932–942.
   PubMed Web of Science ®Google Scholar
• Son SK, Lee NR, Ko J-H, et al. Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2018;73:2631e42.
   Web of Science ®Google Scholar
• Bassetti M, Giacobbe DR, Patel N, et al. Efficacy and safety of meropenem-vaborbactam versus best available therapy for the treatment of carbapenem-resistant enterobacteriaceae infections in patients without prior antimicrobial failure: a post hoc analysis. Adv Ther. 2019;36:1771–1777.
   PubMed Web of Science ®Google Scholar
• Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection. JAMA. 2018;319:788–799.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and safety of meropenem–vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7:439–455.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Vena A, Russo A, et al. Rational approach in the management of Pseudomonas aeruginosa infections. Curr Opin Infect Dis. 2018 Dec;31(6):578–586.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Vena A, Castaldo N, et al. New antibiotics for ventilator-associated pneumonia. Curr Opin Infect Dis. 2018 Apr;31(2):177–186.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Peghin M, Carnelutti A, et al. How should we treat HAP/VAP caused by carbapenemase-producing enterobacteriaceae? Semin Respir Crit Care Med. 2017;38:301–310.
   PubMed Web of Science ®Google Scholar
• Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis. 2020;70:1799–1808.
   PubMed Web of Science ®Google Scholar
• Vena A, Castaldo N, Bassetti M. The role of new β-lactamase inhibitors in gram-negative infections. Curr Opin Infect Dis. 2019;32:638–646.
   PubMed Web of Science ®Google Scholar
• Tuon FF, Rocha JL, Formigoni-Pinto MR. Pharmacological aspects and spectrum of action of ceftazidime–avibactam: a systematic review. Infection. 2018;46:165–181.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Rodriguez-Baňo J. The use of noncarbapenem β-lactams for the treatment of extended-spectrum β-lactamase infections. Clin Infect Dis. 2017;64:972–980.
   PubMed Web of Science ®Google Scholar
• Sader HS, Castanheira M, Flamm RK, et al. Antimicrobial activity of ceftazidime-avibactam against gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob Agents Chemother. 2014;58:1684–1692.
   PubMed Web of Science ®Google Scholar
• Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18:285–295.
   PubMed Web of Science ®Google Scholar
• Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16:661–673.
   PubMed Web of Science ®Google Scholar
• Wagenlehner FM, Sobel JD, Newell P, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis. 2016;63:754–762.
   PubMed Web of Science ®Google Scholar
• Vena A, Giacobbe DR, Castaldo N, et al. Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant gram-negative bacteria other than carbapenem-resistant enterobacterales. Antibiotics (Basel). 2020;9:71
   PubMed Web of Science ®Google Scholar
• Hirsch EB, Brigman HV, Zucchi PC, et al. Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centers. J Glob Antimicrob Resist. 2020;S2213–7165(20):30109.
   Google Scholar
• Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385:1949–1956.
   PubMed Web of Science ®Google Scholar
• Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60:1462–1471.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Nováček M, Kivistik Ü, et al. Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019;19:1299–1311.
   PubMed Web of Science ®Google Scholar
• Popejoy MW, Paterson DL, Cloutier D, et al. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae : a pooled analysis of Phase 3 clinical trials. J Antimicrob Chemother. 2017;72:268–272.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Vena A, Giacobbe DR, et al. Ceftolozane/tazobactam for treatment of severe ESBL-producing enterobacterales infections: a multicenter nationwide clinical experience (CEFTABUSE II Study). Open Forum Infect Dis. 2020 Apr 21;7(5):ofaa139.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Castaldo N, Cattelan A, et al. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. Int J Antimicrob Agents. 2019 Apr;53(4):408–415
   PubMed Web of Science ®Google Scholar
• Sato T, Yamawaki K. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis. 2019;69:S538–43.
   PubMed Web of Science ®Google Scholar
• Yamano Y. In vitro activity of cefiderocol against a broad range of clinically important gram-negative bacteria. Clin Infect Dis. 2019;69:S544–51.
   PubMed Web of Science ®Google Scholar
• Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18:1319–1328.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Ariyasu M, Binkowitz B, et al. Designing a pathogen-focused study to address the high unmet medical need represented by carbapenem-resistant gram-negative pathogens - the international, multicenter, randomized, open-label, phase 3 CREDIBLE-CR study. Infect Drug Resist. 2019 Nov 21;12:3607–3623
   PubMed Web of Science ®Google Scholar
• Alosaimy S, Abdul‐Mutakabbir JC, Kebriaei R, et al. Evaluation of eravacycline: a novel fluorocycline. Pharmacother J Human Pharmacol Drug Ther. 2020;40:221–238.
   Google Scholar
• Morrissey I, Olesky M, Hawser S, et al. In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob Agents Chemother. 2019;63:64.
   Google Scholar
• Montravers P, Zappella N, Tran-Dinh A. Eravacycline for the treatment of complicated intra-abdominal infections. Expert Rev Anti Infect Ther. 2019;17:851–863.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Baxter MR, Adam HJ, et al. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014–2015. Diagn Microbiol Infect Dis. 2018;91:55–62.
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Ramesh MK, Cesnauskas G, et al. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014;58(4):1847–1854
   PubMed Web of Science ®Google Scholar
• Solomkin J, Evans D, Slepavicius A, et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating Gram-negative infections treated with eravacycline (IGNITE 1) trial: A randomized clinical trial. JAMA Surg. 2017;152(3):224–232
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Gardovskis J, Lawrence K, et al. IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs. meropenem in the treatment of complicated intra-abdominal infections. Clin Infect Dis. 2019;69(6):921–929
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Steenbergen J, Zhanel GG. Microbiology and preclinical review of omadacycline. Clin Infect Dis. 2019;69:S6–15.
   PubMed Web of Science ®Google Scholar
• O’Riordan W, Green S, Overcash JS, et al. Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med. 2019;380:528–538.
   PubMed Web of Science ®Google Scholar
• Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380:517–527.
   PubMed Web of Science ®Google Scholar
• Chambers HF. Omadacycline — the Newest Tetracycline. N Engl J Med. 2019;380:588–589.
   PubMed Web of Science ®Google Scholar
• Shaeer KM, Zmarlicka MT, Chahine EB, et al. Plazomicin: a next‐generation aminoglycoside. Pharmacother J Human Pharmacol Drug Ther. 2019;39:77–93.
   Google Scholar
• Castanheira MMR, Doyle TB, Streit JM, et al. Plazomicin activity against Enterobacteriaceae collected from Europe, Latin America, and Asia-Pacific during 2016, including those with aminoglycoside and beta-lactam resistance mechanisms [Poster P0093]. Presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain, April 21–24, 2018.
   Google Scholar
• Connolly LE, Riddle V, Cebrik D, et al. A multicenter, randomized, double-blind, phase 2 study of the efficacy and safety of plazomicin compared with levofloxacin in the treatment of complicated urinary tract infection and acute pyelonephritis. Antimicrob Agents Chemother. 2018;62(4):e01989–17. pii:
   PubMed Web of Science ®Google Scholar
• Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med. 2019;380:729–740.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Russo A, et al. New antibiotics for pneumonia. Clin Chest Med. 2018;39:853–869.
   PubMed Web of Science ®Google Scholar
• Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42:S82–9.
   PubMed Web of Science ®Google Scholar
• Metan G, Zarakolu P, Cakir B, et al. Clinical outcomes and therapeutic options of bloodstream infections caused by extended spectrum beta-lactamase-producing Escherichia coli. Int J Antimicrob Agents. 2005;26:254–257.
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Patel JB, Bilker WB, et al. Extended-spectrum betalactamase- producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32:1162–1171.
   PubMed Web of Science ®Google Scholar
• Kang CI, Kim SH, Kim DM, et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum betalactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2004;25:860–867.
   PubMed Web of Science ®Google Scholar
• Falcone M, Bassetti M, Tiseo G, et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. Crit Care. 2020;24:29.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A, et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med. 2014;40:32–40.
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P. Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock–does the dose matter? Crit Care. 2009;13:214
   PubMed Web of Science ®Google Scholar
• Falcone M, Russo A, Iacovelli A, et al. Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Microbiol Infect. 2016;22:444–450.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004;39:31–37.
   PubMed Web of Science ®Google Scholar
• Shiber S, Yahav D, Avni T, et al. β-Lactam/β-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2015;70:41–47.
   PubMed Web of Science ®Google Scholar
• López-Cerero L, Picón E, Morillo C, et al. Comparative assessment of inoculum effects on the antimicrobial activity of amoxicillin/clavulanate and piperacillin/tazobactam with ESBL-producing and non-producing Escherichia coli isolates. Clin Microbiol Infect. 2010;16:132–136.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Gutiérrez B, Bonomo RA, Carmeli Y, et al. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. J Antimicrob Chemother. 2016;71:1672–1680.
   PubMed Web of Science ®Google Scholar
• Harris PNA, Pezzani MD, Gutiérrez-Gutiérrez B, et al. ESGBIS/REIPI/INCREMENT group. Geographical variation in therapy for bloodstream infections due to multidrug-resistant enterobacteriaceae: a post hoc analysis of the INCREMENT study. Int J Antimicrob Agents. 2017;50:664–672.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Bassetti M, et al. Identifying patients harborin extended-spectrum-betalactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother. 2011;55:3485–3490.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Carnelutti A, et al. Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control. Expert Rev Anti Infect Ther. 2018;16:749–761.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Vena A, et al. Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteria. Curr Opin Crit Care. 2018;24:385–393
   PubMed Web of Science ®Google Scholar
• Bassetti M, Russo A, Carnelutti A, et al. Antimicrobial resistance and treatment: an unmet clinical safety need. Expert Opin Drug Saf. 2018;17:669–680.
   PubMed Web of Science ®Google Scholar
• Titecat M, Liang X, Lee C, et al. High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors. J Antimicrob Chemother. 2016;71:2874–2882.
   PubMed Web of Science ®Google Scholar
• Gao J, Liang L, Zhu Y, et al. Ligand and structure-based approaches for the identification of peptide deformylase inhibitors as antibacterial drugs. Int J Mol Sci. 2016;17:1141.
   PubMed Web of Science ®Google Scholar
• Cassotta A, Goldstein JD, Durini G, et al. Broadly reactive human CD4+ T cells against Enterobacteriaceae are found in the naïve repertoire and are clonally expanded in the memory repertoire. Eur J Immunol. 2020 Nov 23; Epub ahead of print. PMID: 33226131. DOI:https://doi.org/10.1002/eji.202048630..
   Google Scholar
• Alessandri F, Pugliese F, Angeletti S, et al. Procalcitonin in the assessment of ventilator associated pneumonia: a systematic review. Adv Exp Med Biol. 2020 Oct 9; Epub ahead of print. DOI:https://doi.org/10.1007/5584_2020_591..
   PubMedGoogle Scholar
• Bassetti M, Russo A, Righi E, et al. Role of procalcitonin in bacteremic patients and its potential use in predicting infection etiology. Expert Rev Anti Infect Ther. 2019;17:99–105.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Russo A, Righi E, et al. Role of procalcitonin in predicting etiology in bacteremic patients: report from a large single-center experience. J Infect Public Health. 2020;13:40–45.
   PubMed Web of Science ®Google Scholar
• Russo A, Bassetti M, Bellelli V, et al. Efficacy of a fosfomycin-containing regimen for treatment of severe pneumonia caused by multidrug-resistant acinetobacter baumannii: a prospective, observational study. Infect Dis Ther. 2020 Oct 17;1–14. Epub ahead of print. DOI: https://doi.org/10.1007/s40121-020-00357-8.
   Google Scholar
• Russo A, Marincola Cattaneo F, Brunetti G, et al. Clinical features and outcome of difficult-to-treat infections in a high-intensity medical care ward. Minerva Med. 2020 Mar 12; Epub ahead of print. DOI:https://doi.org/10.23736/S0026-4806.20.06467-8..
   PubMedGoogle Scholar
• Russo A, Bassetti M, Ceccarelli G, et al. Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: clinical features, therapy and outcome from a multicenter study. J Infect. 2019;79:130–138.
   PubMed Web of Science ®Google Scholar
• Russo A, Giuliano S, Ceccarelli G, et al. Comparison of septic shock due to multidrug-resistant acinetobacter baumannii or klebsiella pneumoniae carbapenemase-producing k. pneumoniae in intensive care unit patients. Antimicrob Agents Chemother. 2018;62:e02562–17.
   PubMed Web of Science ®Google Scholar